November 11, 2021 5:23pm
The push/pull didn’t quite work with half the market closed (the bond market) for Veterans Day)
Pre-open indication results: 5 HITs, 2 MISS
The Biostage (BSTG) Chronicles: closed down -$0.22 with 2,005 shares traded after Wednesday’s +$0.18 after being “pumped/promoted” with 2,006 shares traded, Tuesday’s -$0.03 with 3,304 shares traded following Monday’s +$0.07 with 7,0882 shares traded and last Friday’s flat $0.00 at $2.60 with 9,003 shares traded. Where is the SEC and Nasdaq monitoring?
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing. Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?
To those who serve and have served, always remember and respect Veteran’s Day
The Dow closed DOWN -158.71 points (-0.4%); the S&P closed UP +2.56 points (+0.06%) while the Nasdaq closed UP +81.58 points (+0.52%)
Henry’omics:
The Nasdaq and S&P rebounded Thursday as the Dow dived …
The bond market was closed in observance of Veterans Day, and in the absence of economic data and with Q3 earnings season winding down, there were few catalysts to move markets in either direction.
Note: Biostage (BSTG) closed down -$0.22 with 2,005 shares traded after Wednesday’s up +$0.18 with 2,006 shares traded after Tuesday’s -$0.03 with 3,304 shares traded after Monday’s +$0.07 after being up +$0.60 with 7,082 shares traded, Friday’s flat $0.00 with 9,003 shares traded, Thursday’s flat at $2.60 with 82 shares traded, Wednesday’s down -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded, flat again $0.00 on Monday with 80 shares traded to $3.10 after last Friday’s 162 shares traded, Thursday’s 95 shares traded and previous Wednesday’s move from -$0.40 with 216 shares traded until the “pump” was turned-on with 1,676 shares traded to close +$0.10 – where is the SEC?
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Thursday opened positive at 21/10, 3 flats and 1 acquired, stayed barely positive at the mid-day at 17/116, 1 flat and 1 acquired, ending with a negative close of 15/18, 1 flat and 1 acquired;
RegMed Investors’ (RMi) pre-open: “a weak aftermarket underwhelms expectation. Question, is there a bounce after a trounce and how many?” … https://www.regmedinvestors.com/articles/12179
Pre-open indication results: 5 HITs: < Biostage (BSTG -$0.22); SELL Into Strength: Chinook Therapeutics (KDNY +$0.02), BioLife Solutions (BLFS -$0.85), Editas Medicine (EDIT +$0.35), Intellia Therapeutics (NTLA +$3.62)> and 2 MISS < AxoGen (AXGN -$0.26), Global Blood Therapeutics (GBT -$0.62)
Key Metric - volume:
Sector volume HIGH with 2 of the 15-upside having higher than the 3-month average volume with LOW volume of 4 of 18-downside having higher than the 3-month average volume;
There are clear winners and losers
Jumping with share pricing momentum (10 of 15):
- Intellia Therapeutics (NTLA +$3.62 after Wednesday’s -$11.58, Tuesday’s +$2.29 and Monday’s +$0.59),
- Ultragenyx (RARE +$1.74),
- ReNeuron (RENE.L +$1.00 after Wednesday’s -$3.50),
- Vericel (VCEL +$0.65),
- Ionis Pharmaceuticals (IONS +$0.37),
- Editas Medicine (EDIT +$0.35 after Wednesday’s -$2.67),
- bluebird bio (BLUE +$0.31 after Wednesday’s +$0.43, Tuesday’s +$0.18 and Monday’s -$2.40),
- Sage Therapeutics (SAGE +$0.31 after Wednesday’s -$1.36, Tuesday’s -$1.05 and Monday’s -$0.73),
- Verastem (VSTM +$0.25),
- Regenxbio (RGNX +$0.20),
Hammered in today’s market (11 of 18):
- Alnylam Pharmaceuticals (ALNY -$3.43 after Wednesday’s -$7.67, Tuesday’s -$4.05 and Monday’s +$0.72),
- BioLife Solutions (BLFS -$0.85 after Wednesday’s -$3.90 after Tuesday’s +$0.28 and Monday’s -$0.59),
- uniQure NV (QURE -$0.62 after Wednesday’s -$0.85, Wednesday’s -$0.85 and Tuesday’s -$0.96),
- Global Blood Therapeutics (GBT -$0.62 after Wednesday’s -$0.87 after Tuesday’s -$1.94),
- Cellectis SA (CLLS -$0.35),
- AxoGen (AXGN -$0.26),
- Biostage (BSTG -$0.22),
- Homology Medicine (FIXX -$0.13),
- Fate Therapeutics (FATE -$0.09 after Wednesday’s -$4.51, Tuesday’s +$0.23 and Monday’s +$1.77),
- Mesoblast (MESO +$0.08),
- Bellicum Pharmaceuticals (BLCM -$0.05 after Wednesday’s +$0.03),
Closing Flat:
- 2 – Biostage (BSTG), Brainstorm Cell Therapeutics (BCLI) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Thursday, the IBB closed down -0.06% and XBI closed up +0.12%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was down -1.07 points or -5.71% at 17.66
November, the second month of Q4/21:
Thursday closed negative with 15 incliners, 18 decliners, 1 flat and 1 acquired
Wednesday closed negative with 4 incliners, 30 decliners and 1 acquired
Tuesday closed negative with 9 incliners, 24 decliners, 1 flat and 1 acquired
Monday (11/8) closed negative with 16 incliners, 17 decliners, 1 flat and 1 acquired
The BOTTOM LINE: another miss of a sector close …
It's not surprising that after what has been a bad run of negative closes – six (6) not an unusual run for the sector undergoing an earnings proctology examination.
As I stated in this morning’s post, “sector weakness should/could unfold some of the oversold”.
Expected Q3 earnings …
We are seeing to date,
- Two (2) net income – Bellicum Pharmaceuticals (BLCM) and BioLife Solutions (BLFS)
- Twenty-one (21) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Cellectis SA (CLLS), Editas Medicine (EDIT), Applied Genetic Technologies (AGTC), Vericel (VCEL) and today’s … BioLife Solutions (BLFS)>
- Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings remaining with ... Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
